Aircraft Engine MRO Market Trends Forecast Analysis by Manufacturers, Regions, Type and Application to 2021

Submit the press release

Aircraft Engine MRO market analysis report speaks about the manufacturing process. The process is analysed thoroughly with four points Manufacturers, regional analysis, Segment by Type & Applications and the actual process of whole Aircraft Engine MRO industry.

A complete analysis of the competitive landscape of the Aircraft Engine MRO Market is provided in the report. This section includes company profiles of market key players. The profiles include contact information, gross, capacity, product details of each firm, price, and cost of Aircraft Engine MRO Industry are covered.

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Aircraft Engine MRO Market Research Report @   http://360marketupdates.com/10385327

Aircraft Engine MRO is the description of maintenance repair and overhaul to aircraft engine, maintenance, repair and overhaul (MRO) is a key activity in the lifecycle of its engines. Because of the typically long operational lifetimes expected from these costly assets, MRO is necessary to maintain these systems in a safe and functional condition, so that they can fulfill the operational role that they were designed for.

Aircraft Engine MRO Market Segment by Manufacturers, this report covers

GE Aviation

Pratt & Whitney Division

Honeywell Aerospace

Rolls Royce

Delta TechOps

MTU Maintenance and many more

Get Sample PDF of Aircraft Engine MRO Market Report @

http://www.360marketupdates.com/enquiry/request-sample/10385327

Scope of the Report:

This report focuses on the Aircraft Engine MRO in Global market, especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Aircraft Engine MRO Market Segment by Regions, regional analysis covers

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America, Middle East and Africa

Aircraft Engine MRO Market report provides application, type impact on market. Also research report covers the present scenario of Aircraft Engine MRO Market Consumption forecast, by regional market, type and application, with sales and revenue, from 2016 to 2021.

Aircraft Engine MRO Market Segment by Type, covers

Maintenance

Repair

Overhaul

Aircraft Engine MRO Market Segment by Applications, can be divided into

Air Transport

BGA

Have Any Query? Ask Our Expert for Aircraft Engine MRO Market Report @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/10385327

Key questions answered in the report:

What will the market growth rate of Aircraft Engine MRO market in 2020?

What are the key factors driving the global Aircraft Engine MRO market?

What are sales, revenue, and price analysis of top manufacturers of Aircraft Engine MRO market?

Who are the distributors, traders and dealers of Aircraft Engine MRO market?

Who are the key vendors in Aircraft Engine MRO market space?

What are the Aircraft Engine MRO market opportunities and threats faced by the vendors in the global Aircraft Engine MRO market?

What are sales, revenue, and price analysis by types, application and regions of Aircraft Engine MRO market?

What are the market opportunities, market risk and market overview of the Aircraft Engine MRO market?

No. of Report pages: 114

Price of Report: $ 3480 (Single User Licence)

Ask for Discount @  http://www.360marketupdates.com/enquiry/request-discount/10385327

About 360 Market Updates:

360 Market Updates is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Contact–

Mr. Ameya Pingaley
360 Market Updates
+1 408 520 9750
Email – sales@360marketupdates.com

Rolling Stock Market Growth Analysis by Manufacturers, Regions, Type and Application, Forecast Analysis to 2021

Submit the press release

Rolling Stock market analysis report speaks about the manufacturing process. The process is analysed thoroughly with four points Manufacturers, regional analysis, Segment by Type & Applications and the actual process of whole Rolling Stock industry.

A complete analysis of the competitive landscape of the Rolling Stock Market is provided in the report. This section includes company profiles of market key players. The profiles include contact information, gross, capacity, product details of each firm, price, and cost of Rolling Stock Industry are covered.

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Rolling Stock Market Research Report @   http://360marketupdates.com/10382841

Rolling Stock originally referred to any vehicles that move on a railway. In this report, rolling stock includes locomotive (diesel type and electric type), rapid transit vehicles (DMU, EMU, LRV and Metro), passenger coaches and freight wagons. Today, rolling stock is more and more important to the modern transportation.

Rolling Stock Market Segment by Manufacturers, this report covers

CRRC

Bombardier

Alstom

Siemens

GE Transportation

Hyundai Rotem

Transmashholding

Stadler Rail AG and many more

Get Sample PDF of Rolling Stock Market Report@

http://www.360marketupdates.com/enquiry/request-sample/10382841

Scope of the Report:

This report focuses on the Rolling Stock in Global market, especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Rolling Stock Market Segment by Regions, regional analysis covers

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America, Middle East and Africa

Rolling Stock Market report provides application, type impact on market. Also research report covers the present scenario of Rolling Stock Market Consumption forecast, by regional market, type and application, with sales and revenue, from 2016 to 2021.

Rolling Stock Market Segment by Type, covers

Diesel Locomotive

Electric Locomotive

DMU (Diesel Multiple Unit)

EMU (Electric Multiple Unit)

LRV (Light Rail Vehicle)

Metro

Passenger Coaches

Freight Wagons

Have Any Query? Ask Our Expert for Rolling Stock Market Report @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/10382841

Rolling Stock Market Segment by Applications, can be divided into

Transportation Industry.

Key questions answered in the report:

What will the market growth rate of Rolling Stock market in 2020?

What are the key factors driving the global Rolling Stock market?

What are sales, revenue, and price analysis of top manufacturers of Rolling Stock market?

Who are the distributors, traders and dealers of Rolling Stock market?

Who are the key vendors in Rolling Stock market space?

What are the Rolling Stock market opportunities and threats faced by the vendors in the global Rolling Stock market?

What are sales, revenue, and price analysis by types, application and regions of Rolling Stock market?

What are the market opportunities, market risk and market overview of the Rolling Stock market?

No. of Report pages: 114

Price of Report: $ 3480 (Single User Licence)

Ask for Discount @  http://www.360marketupdates.com/enquiry/request-discount/10382841

About 360 Market Updates:

360 Market Updates is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Contact–

Mr. Ameya Pingaley
360 Market Updates
+1 408 520 9750
Email – sales@360marketupdates.com

ANSYS Spurs Pervasive Engineering Simulation with Release 18

Submit the press release

Ansys's picture

Printer-friendly versionPrinter-friendly version

PITTSBURGH, Jan. 31, 2017 – Engineers, from the novice to the highly experienced, can now use engineering simulation software across the entire product lifecycle with the newly released ANSYS® 18. This next generation of ANSYS‘ (NASDAQ: ANSS) industry-leading engineering simulation solutions builds upon decades of cutting-edge technology for the most complete and accurate digital prototypes across all major physics, electronics and embedded software areas. This feature-rich release expands the boundaries of simulation upfront in the development process to digital exploration as well as downstream with digital twins, expanding simulation to the operations and maintenance of products.

Today’s industries are undergoing a fundamental transformation in manufacturing and product development. Trends like the Internet of Things, additive manufacturing and machine learning are merging the physical and digital worlds, creating an unprecedented pace of product innovation. The opportunity is immense, but also creates incredible levels of complexity across the entire product lifecycle.

Emerging technologies and changing customer expectations are spurring a major transformation in the way products are manufactured and brought to market. Simulation is playing a critical role giving engineers the necessary tools to innovate and transform products across their entire lifecycle,” said Ajei Gopal, president and CEO of ANSYS. “With ANSYS 18, customers can use simulation upfront in the development process to quickly evaluate changes in design and downstream of the product lifecycle to analyze real-time operational data – providing companies with game-changing data that in turn furthers innovation, operational efficiency, product quality, as well as cut costs and time to market.”

Simulation is being adopted across the entire product lifecycle, empowering engineers to imagine more options – a trend ANSYS calls pervasive engineering simulation. ANSYS simulation’s increasing ease of use enables more users to take advantage of simulation early in the design process. Its increased scalability empowers users to quickly evaluate thousands of choices for optimal product design. ANSYS 18 also integrates with Internet of Things platforms to simulate digital twins of assets in operation.

“Technology is growing by leaps and bounds and to stay ahead of the curve, simulation will be a critical tool to accomplish more, faster and provide deeper insight into our products. Simulation offers infinite possibilities into understanding our products and we’ve only just scratched the surface to modeling and simulation, said Bob Tickel, director of structural and dynamic analysis of research and technology, Cummins. “We’re doing things today that could only have been imagined just a few years ago and simulation is playing a huge role. ANSYS simulation allows us to make better decisions earlier in the design process to get our design right the first time to produce the best products on time at the lowest cost for our customers.”

Early design decisions lock in most of a product’s costs. Through digital exploration capabilities in ANSYS 18, users can test hundreds of “what-if” concepts early in the design phase and quickly assess product performance for strength, power, thermal, pressure, flow rate, electrical or a number of other performance requirements. Through this digital exploration, designers and product engineers can identify optimal combinations while eliminating outlying designs – saving time and money.

“The telecommunications market is growing fast and ANSYS multiphysics solutions are an exceptionally productive tool with results I can trust,” said Ricardo Damian, engineering director at Jet Towers Telecom. “ANSYS simulation tools are helping us to understand every aspect of the product design, like reducing wind drag, testing different materials, geometrical configurations and testing unusual and odd scenarios. But most importantly, we are learning so much more about our product physics. Thanks to ANSYS software, we are delivering a superior product to customers five times faster than other manufacturers at a competitive price.”

Leading organizations are also expanding their use of simulation into operations by creating digital twins – virtual representations of individual operating assets whose performance and productivity can be improved through simulation technology. Sensors on the machine relay specific operating data — temperature, vibration, impact, loading — to the digital twin. This continuous feedback helps engineers to optimize the operation of a machine or a system and can predict adverse conditions long before they happen – unlocking billions of dollars in production and maintenance optimization. ANSYS 18 in combination with partner applications like, GE Predix and PTC ThingWorx, empowers users to create digital twins and apply predictive analytics to optimize their product’s performance and operations in the field.

“The Industrial Internet provides the opportunity to gain better insight, better control and better decision making over industrial operations and simulation is playing a significant role in that,” said John Magee, chief marketing officer for Predix, GE Digital. “Working with ANSYS has provided us with modeling and simulation capabilities that enable us to collect data and arm our customers with better decision making tools. By combining ANSYS simulation tools with GE’s Predix platform, we are delivering a stronger solution for the industrial world.”

For more information about the features and enhancements available in ANSYS 18, read the latest ANSYS Blog.

About ANSYS, Inc.

ANSYS is the global leader in engineering simulation. We bring clarity and insight to our customer’s most complex design challenges through the broadest portfolio of fast, accurate and reliable simulation tools. Our technology enables organizations in all industries to imagine high-quality, innovative and sustainable product designs that have an accelerated time to market. Founded in 1970, ANSYS employs almost 3000 professionals, more than 700 of them with PhDs in engineering fields such as finite element analysis, computational fluid dynamics, electronics and electromagnetics, embedded software, system simulation and design optimization. Headquartered south of Pittsburgh, U.S.A., ANSYS has more than 75 strategic sales and development locations throughout the world with a network of channel partners in 40+ countries. Visit www.ansys.com for more information.

ANSYS also has a strong presence on the major social channels. To join the simulation conversation, please visit: www.ansys.com/Social@ANSYS

ANSYS and any and all ANSYS, Inc. brand, product, service and feature names, logos and slogans are registered trademarks or trademarks of ANSYS, Inc. or its subsidiaries in the United States or other countries. All other brand, product, service and feature names or trademarks are the property of their respective owners.

Copy this html code to your website/blog to embed this press release.

Bioimaging Market 2017 Global Analysis, Opportunities and Forecast To 2021

Submit the press release

PDF  View as PDF  Print View   

Bioimaging -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021

Bioimaging Industry

Description

Bioimaging report covers Applications and the various modalities of Bioimaging for the global market. The Applications of Bioimaging include Diagnostics and Research and Development. The report provides an in depth analysis of each of the applications and modalities by their respective categories. The study includes estimates and projections for the total global Bioimaging market and also key regional markets that include North America, Europe, Asia-Pacific, Latin America and Rest of World.

Estimates and projections are illustrated graphically. Business profiles of 31 major companies are discussed in the report. The report serves as a guide to global Bioimaging industry, covering 700 plus companies that are engaged in the development and supply of Bioimaging modalities. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/905716-bioimaging-market-research-report

Highlights

The Biomedical Imaging stream would evolve as a pillar for diagnosis; this further improves other techniques that play a competitive role in imaging. The bioimaging market is growing day by day, at around 7% through 2010-2022. Bioimaging techniques are regarded as the most promising advancements in the field of present day healthcare and biomedical research. Bioimaging is being recognized as one of the most comprehensive achievements, which has eased the working conditions of the physicians. In the present medical scenario majority of the diseases are being diagnosed and attended using biomedical imaging techniques. This technique requires a good amount of development to understand the basic functions of the organs in the living system. The main aim of the concept of bioimaging is to provide an effective understanding of the numerous available imaging modalities like X-ray, Commuted Tomography, emission tomography and magnetic resonance imaging. This is done by relating the basic operating principles of these techniques with that of Imaging techniques.

The intricate cellular and molecular signaling practices in the development and homeostasis could only be analyzed using complete analysis of the living organism. These requirements necessitate biomedical research and drug development to possess numerous dynamic processes in cellular physiology, development and disease conditions of living organism by employing bioimaging technologies. Medical imaging implies development of an image of the body or part thereof that has the disease and studying this image of the anatomy vis-a-vis its function in the body. Radiology, endoscopy, thermography, microscopy, radiological sciences, and medical photography, are the normally used biomedical imaging techniques. In addition, techniques such as electroencephalography (EEG) and magnetoencephalography (MEG), which do not generate images, but generate data that could be read as maps for analyzing the abnormal variations in measurements of some process also, form part of biomedical imaging. Molecular imaging is useful for quantitative tests, assessing how much of a drug dosage is required for achieving the target, or how much time is taken for a given reaction.

Though such imaging has potential in several areas, presently it is used for understanding the molecular behavior just before the organism starts showing the symptoms of a disease. This understanding would help in early detection of diseases and infections, thereby reducing the need for drastic measures like surgery or stronger doses of drugs. Molecular bioimaging would pave the way to molecular medicines based on human genomes. It gives the visual evidence of enzyme expressions, function of reporter genes and neurotransmitters, and other processes.

Exclusive 25 % flat discount (Offer valid till 31st March 2017) @ https://www.wiseguyreports.com/check-discount/905716-bioimaging-market-research-report

Key Players

Analogic Corporation (USA)

Arcoma AB (Sweden)

Bayer HealthCare AG (Germany)

Bracco SpA (Italy)

Carestream Health, Inc. (USA)

Carl Zeiss Meditec AG (Germany)

Cell>Point LLC (USA)

Digirad Corporation (USA)

Esaote SpA (Italy)

FEI Company (USA)

FONAR Corporation (USA)

FUJIFILM SonoSite, Inc. (USA)

FUJIFILM VisualSonics, Inc. (Canada)

Gamma Medica, Inc. (USA)

GE Healthcare Ltd. (UK)

Guerbet SA (France)

Hitachi Medical Corporation (Japan)

Hologic, Inc. (USA)

Jubilant DraxImage, Inc. (Canada)

Kereos, Inc. (USA)

Koninklijke Philips Electronics N.V. (The Netherlands)

Lantheus Medical Imaging (USA)

Mallinckrodt plc (Ireland)

Mindray Bio-Medical Electronics Co., Ltd. (China)

Neusoft Group Ltd. (China)

Positron Corporation (USA)

Samsung Medison Co., Ltd. (South Korea)

Shimadzu Corporation (Japan)

Siemens Medical Solutions, Inc. (USA)

Swissray Medical AG (Switzerland)

Toshiba Medical Systems Corporation (Japan)

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=905716

Why buy this Report

This report may help Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to –

Identify Market Opportunities
Review and Analyze Global and Regional Markets
Gauge Market Potential for your Products
Identify Competition
Use Market Research for exploring new areas
Acquire Meaningful Guidelines for Strategic Planning
Gear up for Market Entry
Get Actionable Information
Analytics and data presented in each report pertain to several parameters such as –

Global and Regional Market Sizes, Market Shares, Market Trends
Product (Global and Regional) Market Sizes, Market Shares, Market Trends
Technology Trends
Corporate Intelligence
Key Companies By Sales, Brands, Products
Other Strategic Business Affecting Data
Continued…

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

Contact Info:
Name: NORAH TRENT
Email: Sales@Wiseguyreports.Com
Organization: WISE GUY RESEARCH CONSULTANTS PVT LTD
Address: Pune 411028 , Maharashtra, India
Phone: +1-646-845-9349 / +44 208 133 9349

Source URL: http://marketersmedia.com/bioimaging-market-2017-global-analysis-opportunities-and-forecast-to-2021/164988

For more information, please visit https://www.wiseguyreports.com/sample-request/905716-bioimaging-market-research-report

Source: MarketersMedia

Release ID: 164988

Recent Press Releases By The Same User

DannyPettry.com is Holding a Free Webinar for Recreational Therapy Month (Fri 27th Jan 17)

Do-it-Yourself Miracle Truss Buildings Storage Building Kits Available Online (Fri 27th Jan 17)

Advanced Driver Assistance Systems (ADAS) Market 2017 Global Analysis, Opportunities and Forecast To 2021 (Fri 27th Jan 17)

Tissue Sealants Market 2017 Global Analysis, Opportunities and Forecast To 2021 (Fri 27th Jan 17)

Biopesticides Market 2017 Global Analysis, Opportunities and Forecast To 2021 (Fri 27th Jan 17)

Reactors Market Forecast to 2021 with Key Companies Profile, Supply, Demand, Cost Structure, and SWOT Analysis (Fri 27th Jan 17)

Home Healthcare Market Growing at Rapid Pace and Reach USD 122 Billion by 2022 with CAGR of 9%

Submit the press release

PDF  View as PDF  Print View   

Global Home Healthcare Market is growing at a rapid pace and is expected to grow at a CAGR of around 9% by the end of the forecasted period from 2016-2022

Market Highlights
The global home healthcare market has been examined to be rapidly growing and is expected to continue this growth in future. In the home healthcare industry, the growing interest for affordable healthcare solutions is one of the key factors driving the development of this market presently and is expected to continue this growth in the future. In the recent decade, the cost of healthcare has been rising relentlessly around the globe. In developed nations like the United States, the healthcare cost expanded quickly, and this growth is due to increment in the costs of medications, therapeutic devices, and healthcare center administrations. Home healthcare solutions includes health monitoring devices and other services that can be used by patients in the comfort of home and at a fraction of the cost compared to the cost of hospital care. Though these solutions have assured limitations in case of acute symptoms and diseases, majority of the cases can easily be solved with the help of home healthcare solutions.

It is projected that factors such as technological advancements in the field of home healthcare is expected to boost the market in the coming future. In recent times there have been growth in home healthcare devices with new devices coming in such as safety lancets which permits patients to monitor their glucose levels in their homes rather than taking help of any healthcare professional or a diagnostic center. Home Healthcare Market Growing at Rapid Pace and Reach USD 122 Billion by 2022 with CAGR of 9%

Market Players:
o Johnson & Johnson
o Omron Healthcare
o Philips
o McKesson
o Roche
o HTL Strefa
o BD
o Sarstead AG
o eCaring
o Kindred at Home
o F. Hoffmann-La Roche Ltd
o GE Healthcare
o Interim HealthCare Inc.
o Linde Group (Healthcare)

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/2030

Regional Analysis:
Depending on geographic region, home healthcare market is segmented into four key regions: America, Europe, Asia-Pacific, Middle East & Africa. Globally America is the largest market for home healthcare. North American region is the leading market as countries like U.S. and Canada having strict regulation in terms of medical devices and services thus improving the quality of the devices and products, also improves the efficiency and quality of these and services offered. Europe is expected to be second largest market globally for home healthcare which is expected to continue its growth in the coming future. Asia Pacific region is expected to be fastest growing region in Home Healthcare Market.

Segmentation:
Home healthcare market has been segmented on the basis of type which comprises of products, services, solutions and others. On the basis of applications, the market is segmented into wound care, patient education, nutrition therapy and monitoring among others.

Intended Audience
o Home healthcare devices manufacturers and suppliers
o Research and development (R&D) companies
o Research laboratories
o Government and independent regulatory authorities
o Market research and consulting service providers
o Academic institutes and universities
o Home healthcare service providers

Browse Report @ https://www.marketresearchfuture.com/reports/home-healthcare-market

The market for home healthcare is growing at a rapid pace and is expected to continue its growth similarly in the coming future. Ageing population is high world-wide. The effect of ageing includes decreasing mortality and most importantly declining fertility. As per the United Nations statistics, the global ageing population (aged 60 years and over) has increased by 9.2 percent in 1990 to 11.7 per cent in 2013 and will reach 21.1 percent by 2050. As the ageing population increases, the need for home healthcare also increase since home monitoring is convenient form of health monitoring for the elderly population.

Related Report
Global mHealth Market is expected to reach $ 21.71Billion by 2022 https://marketresearchfuture.com/reports/mobile-health-market

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Akash Anand
Email: akash.anand@marketresearchfuture.com
Organization: Market Research Future
Address: Office No. 524/528, Amanora Chambers, Magarpatta Road, Hadapsar Pune
Phone: +1 646 845 9312

Source URL: http://marketersmedia.com/home-healthcare-market-growing-at-rapid-pace-and-reach-usd-122-billion-by-2022-with-cagr-of-9/165027

For more information, please visit https://www.marketresearchfuture.com/reports/home-healthcare-market

Source: MarketersMedia

Release ID: 165027

Recent Press Releases By The Same User

DannyPettry.com is Holding a Free Webinar for Recreational Therapy Month (Fri 27th Jan 17)

Do-it-Yourself Miracle Truss Buildings Storage Building Kits Available Online (Fri 27th Jan 17)

Advanced Driver Assistance Systems (ADAS) Market 2017 Global Analysis, Opportunities and Forecast To 2021 (Fri 27th Jan 17)

Tissue Sealants Market 2017 Global Analysis, Opportunities and Forecast To 2021 (Fri 27th Jan 17)

Biopesticides Market 2017 Global Analysis, Opportunities and Forecast To 2021 (Fri 27th Jan 17)

Reactors Market Forecast to 2021 with Key Companies Profile, Supply, Demand, Cost Structure, and SWOT Analysis (Fri 27th Jan 17)

Healthcare Big Data Analytics Market Share, Leading Players Analysis, Industry Financials Estimation and Forecast to 2027

Submit the press release

PDF  View as PDF  Print View   

Healthcare Big Data Analytics Market by components (Software, hardware and others) by end users (Healthcare, Pharmaceuticals and others) by applications (Clinical Data Analytics & financial Data Analytics) and by types:- Global forecast to 2027

Market Overview
The global healthcare big data analytics market, which broadly utilizes information for qualitative and quantitative analysis, is experiencing an industry change from volume-based solutions and repayment to esteem based pharmaceuticals and repayment. Factors, for example, the sudden accentuation on a more enhanced quality healthcare, diminished length-of-stay at hospitals, lower expenses of health and prescription, and misrepresentation recognition, is the essential requests of payers of this innovation. Moreover, higher incentives for medication, combination of big data in healthcare, and innovative headways, among others are a portion of alternate drivers of this market.

Key Players
o IBM
o Cerner Corporation
o Cognizant
o Dell
o Epic System Corporation
o GE Healthcare
o McKesson
o Optum
o Philips
o Siemens
o Xerox

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/726

Market Growth Influencer
Global Healthcare Big Data Analytics Market has seen a tremendous growth in the recent years. Various factors, such as, increase in pressure to control healthcare costs, meaningful use impetuses, accessibility of big data in healthcare industry, innovative headways or technological advancements, and expansion in funding ventures are moving the development of global healthcare big data analytics market. Then again, the operational crevice amongst payers and suppliers, absence of skilled people, and high cost of analytics arrangements may confine market development. A few strengths are setting off the support in the general interest for healthcare Big Data analytics in the industry. Government agencies are empowering the utilization of Big Data in the healthcare industries. The Department of Health and Human Services (HHS) under the Health Data Initiative (HDI) is beginning to discharge information from organizations like the Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) keeping in mind the end goal to get to open information of patients for clinical trials and other examination exercises.

Market Segmentation
By Types
1. Platform/ Technology
o Prescriptive Analytics
o Predictive Analytics
o Descriptive Analytics

By applications
1. Clinical Data Analytics
o Quality Healthcare
o Professional Performance Evaluation
o Reducing the Incidence of Medical Errors

2. Financial Data Analytics
o Risk Management Analytics
o Revenue Generation Analytics

By Components
o Software
o Services
o Consulting

By End Users
o Healthcare
o Pharmaceuticals

Browse Report @ https://www.marketresearchfuture.com/reports/healthcare-big-data-analytics-market

Healthcare Big Data Analytics Market: Regional Analysis
North America: In 2015, North America is required to lead the Healthcare Big Data Analytics Market and acquire the highest rate of CAGR. The high development of this area is ascribed to elected healthcare commands empowering the adoption of HCIT solutions or arrangements, positive government support, huge funding ventures for big data analytics, and the rising focus on health management population, among others.

Europe: Government Healthcare policies, Emergence of Big Data, rising focus on Data Collection, technological advancement, rising awareness and Electronic Health Record implementations are the major factors driving the European market.

Healthcare Big Data Analytics Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report also gives a broad study of the different market segments and regions.

Related Report
Global Big Data in Healthcare Market Research Report, by Hardware (Routers, VPNs), by Software (EHR, Practice Management), by Analytical service type (Descriptive, Predictive, Prescriptive) by region (Europe, Americas, APAC & MEA) – Forecast to 2027 https://www.marketresearchfuture.com/reports/big-data-healthcare-market

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Akash Anand
Email: akash.anand@marketresearchfuture.com
Organization: Market Research Future
Address: Office No. 524/528, Amanora Chambers, Magarpatta Road, Hadapsar Pune
Phone: +1 646 845 9312

Source URL: http://marketersmedia.com/healthcare-big-data-analytics-market-share-leading-players-analysis-industry-financials-estimation-and-forecast-to-2027/165024

For more information, please visit https://www.marketresearchfuture.com/reports/healthcare-big-data-analytics-market

Source: MarketersMedia

Release ID: 165024

Recent Press Releases By The Same User

DannyPettry.com is Holding a Free Webinar for Recreational Therapy Month (Fri 27th Jan 17)

Do-it-Yourself Miracle Truss Buildings Storage Building Kits Available Online (Fri 27th Jan 17)

Advanced Driver Assistance Systems (ADAS) Market 2017 Global Analysis, Opportunities and Forecast To 2021 (Fri 27th Jan 17)

Tissue Sealants Market 2017 Global Analysis, Opportunities and Forecast To 2021 (Fri 27th Jan 17)

Biopesticides Market 2017 Global Analysis, Opportunities and Forecast To 2021 (Fri 27th Jan 17)

Reactors Market Forecast to 2021 with Key Companies Profile, Supply, Demand, Cost Structure, and SWOT Analysis (Fri 27th Jan 17)

CNB Financial Corporation Reports Year End 2016 Earnings, Highlighted By Strong Organic Loan Growth

Submit the press release

CLEARFIELD, PA–(Marketwired – January 27, 2017) – CNB Financial Corporation (“CNB”) (NASDAQ: CCNE), the parent company of CNB Bank, today announced its earnings for the year ended December 31, 2016. Highlights include the following:

  • Loans of $1.87 billion as of December 31, 2016, including loans acquired from Lake National Bank, which closed in July 2016, of $122.3 million, compared to loans of $1.58 billion as of December 31, 2015. Organic loan growth in 2016 was 10.6%.
  • Deposits of $2.02 billion as of December 31, 2016, including deposits acquired from Lake National Bank of $139.8 million, compared to deposits of $1.82 billion as of December 31, 2015. Organic deposit growth in 2016 was 3.2%.
  • Net interest margin on a fully tax-equivalent basis of 3.78% for the year ended December 31, 2016, compared to 3.73% for the year ended December 31, 2015.
  • Net income of $20.5 million, or $1.42 per share, in 2016, compared to net income of $22.2 million, or $1.54 per share, in 2015.
  • Pre-tax income of $27.8 million in 2016, compared to pre-tax income of $30.4 million in 2015. Pre-tax income excluding the effects of realized gains on the sale of available-for-sale securities and certain one-time costs as disclosed in the non-GAAP reconciliation within the financial tables was $30.4 million in 2016, compared to $30.2 million in 2015.
  • Book value per share of $14.64 as of December 31, 2016 increased 4.5% compared to book value per share of $14.01 as of December 31, 2015.
  • Tangible book value per share of $11.76 as of December 31, 2016 decreased 1.7% compared to tangible book value per share of $11.96 as of December 31, 2015, primarily as a result of the additional intangible assets associated with the acquisition of Lake National Bank as disclosed in the non-GAAP reconciliation within the financial tables. In addition, approximately $0.14 per share of the tangible book value decline on a year-over-year basis is due to a reduction in accumulated other comprehensive income, largely a result of the higher interest rate environment.
  • Non-performing assets of $16.4 million, or 0.64% of total assets as of December 31, 2016, compared to $13.2 million, or 0.58% of total assets, as of December 31, 2015.

In the third quarter of 2016, CNB received regulatory approval to conduct business in the state of New York as Bank on Buffalo, a division of CNB Bank. CNB opened a loan production office in Buffalo, New York in May 2016 and has plans to open a full-service location in downtown Buffalo in the first quarter of 2017 and close the loan production office. Full-service locations in Williamsville, New York and Orchard Park, New York will open in the second quarter of 2017.

On January 20, 2017, CNB announced the sale of its bank branch located in Mt. Hope, Ohio with approximately $6.5 million of deposits and $7.5 million in loans to First Federal Community Bank of Dover, Ohio for a deposit premium of 8.0%. Consummation of the branch sale is subject to a number of closing conditions, including, but not limited to, the receipt of all required regulatory approvals, and is expected to be completed on or before May 31, 2017.

Joseph B. Bower, Jr., President and CEO, stated, “The fourth quarter gave us great loan growth of 15.6% annualized. The growth will provide a positive impact in the first quarter of 2017, but did create a substantial addition to our loan loss provision in the fourth quarter. With the majority of our infrastructure projects now in place, CNB is poised to direct our efforts toward increased profitability and return to more favorable returns of equity and assets. In addition, the shareholders saw a nice increase in share price during the fourth quarter, giving shareholders a total return in 2016 of 53%.”

Net Interest Margin

Net interest margin on a fully tax equivalent basis was 3.84% and 3.78% for the three months and year ended December 31, 2016, compared to 3.73% for both the three months and year ended December 31, 2015. Net accretion included in loan interest income related to acquired loans was $1.1 million and $1.8 million for the three months and year ended December 31, 2016, resulting in an increase in the net interest margin of 20 basis points and 8 basis points, respectively. Net accretion included in loan interest income related to acquired loans was $358 thousand and $2.2 million for the three months and year ended December 31, 2015, resulting in an increase in the net interest margin of 8 basis points and 11 basis points, respectively. In late September 2016, CNB issued $50 million of subordinated debt to help support balance sheet growth. The interest expense on the subordinated debt was $783 thousand for the 3 months and year ended December 31, 2016.

Throughout the current interest rate cycle, CNB has been able to gradually lower its cost of funds, primarily through disciplined deposit pricing and refinancing of long-term borrowings. The cost of interest-bearing liabilities was 69 basis points during the year ended December 31, 2016, compared to 71 basis points during the year ended December 31, 2015.

Asset Quality

During the year ended December 31, 2016, CNB recorded a provision for loan losses of $4.1 million, as compared to a provision for loan losses of $2.6 million for the year ended December 31, 2015. The provision for loan losses was $2.1 million and $668 thousand for the three months ended December 31, 2016 and 2015, respectively. Net chargeoffs during the year ended December 31, 2016 were $4.6 million, as compared to net chargeoffs of $3.2 million during the year ended December 31, 2015, and the ratio of net chargeoffs to average loans was 0.27% and 0.22% for the years ended December 31, 2016 and 2015, respectively.

The increase in chargeoffs in 2016 compared to 2015 was primarily attributable to consumer loans held in CNB’s consumer discount company, Holiday Financial Services Corporation. CNB Bank net chargeoffs totaled $1.7 million and $1.5 million in 2016 and 2015, respectively. Holiday Financial Services Corporation net chargeoffs totaled $2.9 million and $1.7 million in 2016 and 2015, respectively.

During the fourth quarter of 2016, CNB identified a commercial real estate loan that, while performing in accordance with its contractual terms and current with scheduled principal and interest payments, is showing sufficient signs of weakness to be classified as impaired. As of December 31, 2016, the principal balance of the loan is $6.2 million, and the specific loan loss reserve recorded during the quarter is $1.0 million.

Non-Interest Income

Excluding the effects of securities transactions, non-interest income was $16.2 million for the year ended December 31, 2016, compared to $16.6 million for the year ended December 31, 2015. Net realized gains on available-for-sale securities were $1.0 million during the year ended December 31, 2016, compared to $666 thousand during the year ended December 31, 2015. Net realized and unrealized gains on trading securities were $503 thousand during the year ended December 31, 2016, compared to net realized and unrealized losses of $213 thousand during the year ended December 31, 2015.

Non-Interest Expenses

Throughout 2016 and 2015, CNB made numerous infrastructure, personnel, and technology investments to facilitate its continued growth. Total non-interest expenses were $16.5 million and $67.1 million during the three months and year ended December 31, 2016, compared to $15.4 million and $58.8 million during the three months and year ended December 31, 2015. In order to better serve our customers and improve operational efficiencies, CNB completed a core processing system upgrade in May 2016. Included in non-interest expenses in 2016 are $3.7 million of non-recurring items, with costs associated with our core processing system upgrade of $1.7 million, merger related expenses of $486 thousand, and a prepayment penalty associated with the early payoff of long-term borrowings of $1.5 million. Costs for similar items in 2015 totaled $416 thousand in the aggregate.

Salaries and benefits expense increased $2.6 million, or 8.9%, during the year ended December 31, 2016 compared to the year ended December 31, 2015. As of December 31, 2016, CNB had 486 full-time equivalent staff, compared to 436 full-time equivalent staff as of December 31, 2015. The staff added during this period included both customer-facing personnel such as business development and wealth management officers, as well as support department personnel. In addition, CNB retained 20 employees in connection with its acquisition of Lake National Bank.

During the fourth quarter of 2016, CNB recorded an expense related to its directors and executive deferred compensation plan of $560 thousand, compared to an expense of $108 thousand that was recorded for the first nine months of 2016. This increase is primarily attributable to the increase in CNB’s stock price from $21.16 at September 30, 2016 to $26.74 at December 31, 2016 since the most significant component of the plan’s valuation is phantom CNB stock.

About CNB Financial Corporation

CNB Financial Corporation is a financial holding company with consolidated assets of approximately $2.6 billion that conducts business primarily through CNB Bank, CNB Financial Corporation’s principal subsidiary. CNB Bank is a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. CNB Bank operations include a private banking division, three loan production offices, 31 full-service offices in Pennsylvania and northeast Ohio, including ERIEBANK, a division of CNB Bank, 9 full-service offices in central Ohio conducting business as FCBank, a division of CNB Bank, and a loan production office in Buffalo, New York conducting business as Bank on Buffalo, a division of CNB Bank. More information about CNB and CNB Bank may be found on the internet at www.cnbbank.bank.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to CNB’s financial condition, liquidity, results of operations, future performance and business. These forward-looking statements are intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those that are not historical facts. Forward-looking statements include statements with respect to beliefs, plans, objectives, goals, expectations, anticipations, estimates and intentions that are subject to significant risks and uncertainties and are subject to change based on various factors (some of which are beyond CNB’s control). Forward-looking statements often include the words “believes,” “expects,” “anticipates,” “estimates,” “forecasts,” “intends,” “plans,” “targets,” “potentially,” “probably,” “projects,” “outlook” or similar expressions or future conditional verbs such as “may,” “will,” “should,” “would” and “could.” CNB’s actual results may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. For more information about factors that could cause actual results to differ from those discussed in the forward-looking statements, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of and the forward-looking statement disclaimers in CNB’s annual and quarterly reports.

The forward-looking statements are based upon management’s beliefs and assumptions and are made as of the date of this press release. CNB undertakes no obligation to publicly update or revise any forward-looking statements included in this press release or to update the reasons why actual results could differ from those contained in such statements, whether as a result of new information, future events or otherwise, except to the extent required by law. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release might not occur and you should not put undue reliance on any forward-looking statements.

Financial Tables

The following tables supplement the financial highlights described previously for CNB Financial Corporation.

                       (unaudited)                                          
                   Three Months Ended              Twelve Months Ended      
                      December 31,                    December 31,          
             ------------------------------  ------------------------------ 
(Dollars in                                                                 
 thousands,                                                                 
 except                                                                     
 share and                                                                  
 per share                                                                  
 data)                                                                      
                                             (unaudited)                    
                                        %                               %   
                 2016        2015    change      2016        2015    change 
             ----------- ----------- ------  ----------- ----------- ------ 
Income                                                                      
 Statement                                                                  
------------                                                                
Interest                                                                    
 income      $    24,818 $    21,994   12.8% $    94,315 $    87,178    8.2%
Interest                                                                    
 expense           3,809       3,066   24.2%      13,028      12,471    4.5%
             ----------- -----------         ----------- -----------        
 Net                                                                        
  interest                                                                  
  income          21,009      18,928   11.0%      81,287      74,707    8.8%
Provision                                                                   
 for loan                                                                   
 losses            2,111         668  216.0%       4,149       2,560   62.1%
             ----------- -----------         ----------- -----------        
 Net                                                                        
  interest                                                                  
  income                                                                    
  after                                                                     
  provision                                                                 
  for loan                                                                  
  losses          18,898      18,260    3.5%      77,138      72,147    6.9%
             ----------- -----------         ----------- -----------        
                                                                            
Non-interest                                                                
 income                                                                     
 Service                                                                    
  charges on                                                                
  deposit                                                                   
  accounts         1,148         749   53.3%       4,297       4,442   -3.3%
 Other                                                                      
  service                                                                   
  charges                                                                   
  and fees           702       1,160  -39.5%       2,539       3,089  -17.8%
 Wealth and                                                                 
  asset                                                                     
  management                                                                
  fees               789         866   -8.9%       3,087       2,977    3.7%
 Net                                                                        
  realized                                                                  
  gains on                                                                  
  available-                                                                
  for-sale                                                                  
  securities           -         102     NA        1,005         666   50.9%
 Net                                                                        
  realized                                                                  
  and                                                                       
  unrealized                                                                
  gains                                                                     
  (losses)                                                                  
  on trading                                                                
  securities         238         108  120.4%         503        (213)    NA 
 Mortgage                                                                   
  banking            389         262   48.5%       1,095         746   46.8%
 Bank owned                                                                 
  life                                                                      
  insurance          276         342  -19.3%       1,083       1,194   -9.3%
 Card                                                                       
  processing                                                                
  and                                                                       
  interchan-                                                                
  ge income          897         875    2.5%       3,396       3,417   -0.6%
 Other               185         252  -26.6%         686         776  -11.6%
             ----------- -----------         ----------- -----------        
                                                                            
  Total non-                                                                
   interest                                                                 
   income          4,624       4,716   -2.0%      17,691      17,094    3.5%
             ----------- -----------         ----------- -----------        
                                                                            
Non-interest                                                                
 expenses                                                                   
 Salaries                                                                   
  and                                                                       
  benefits         8,289       7,853    5.6%      32,194      29,563    8.9%
 Net                                                                        
  occupancy                                                                 
  expense of                                                                
  premises         2,132       1,643   29.8%       8,064       7,000   15.2%
 FDIC                                                                       
  insurance                                                                 
  premiums           180         321  -43.9%       1,229       1,278   -3.8%
 Core                                                                       
  Deposit                                                                   
  Intangible                                                                
  amortizat-                                                                
  ion                346         230   50.4%       1,125       1,008   11.6%
 Prepayment                                                                 
  penalties                                                                 
  - long-                                                                   
  term                                                                      
  borrowings           -           -     NA        1,506           -     NA 
 Core                                                                       
  processing                                                                
  conversion                                                                
  costs               96         108  -11.1%       1,693         108 1467.6%
 Merger                                                                     
  costs                5         308  -98.4%         486         308   57.8%
 Card                                                                       
  processing                                                                
  and                                                                       
  interchan-                                                                
  ge expenses        219         570  -61.6%       1,889       2,295  -17.7%
 Other             5,188       4,353   19.2%      18,932      17,192   10.1%
             ----------- -----------         ----------- -----------        
  Total non-                                                                
   interest                                                                 
   expenses       16,455      15,386    6.9%      67,118      58,752   14.2%
             ----------- -----------         ----------- -----------        
                                                                            
Income                                                                      
 before                                                                     
 income                                                                     
 taxes             7,067       7,590   -6.9%      27,711      30,489   -9.1%
Income tax                                                                  
 expense           2,027       2,082   -2.6%       7,171       8,292  -13.5%
             ----------- -----------         ----------- -----------        
Net income   $     5,040 $     5,508   -8.5% $    20,540 $    22,197   -7.5%
             ----------- -----------         ----------- -----------        
                                                                            
Average                                                                     
 diluted                                                                    
 shares                                                                     
 outstanding  14,394,109  14,345,926          14,374,260  14,338,737        
                                                                            
Diluted                                                                     
 earnings                                                                   
 per share   $      0.35 $      0.38   -7.9% $      1.42 $      1.54   -7.8%
Cash                                                                        
 dividends                                                                  
 per share   $     0.165 $     0.165    0.0% $     0.660 $     0.660    0.0%
                                                                            
Payout ratio          47%         43%                 46%         43%       
                                                                            
Average                                                                     
 Balances                                                                   
------------                                                                
Loans, net                                                                  
 of unearned                                                                
 income      $ 1,836,234 $ 1,553,980         $ 1,717,224 $ 1,460,163        
Total                                                                       
 earning                                                                    
 assets        2,353,892   2,130,412           2,261,403   2,093,852        
Total assets   2,522,410   2,268,570           2,420,240   2,231,881        
Total                                                                       
 deposits      2,014,248   1,827,710           1,950,014   1,849,203        
Shareholders'                                                                
   equity        214,142     202,130             212,058     197,687        
                                                                            
Performance                                                                 
 Ratios                                                                     
 (quarterly                                                                 
 information                                                                
 annualized)                                                                
------------                                                                
Return on                                                                   
 average                                                                    
 assets             0.80%       0.97%               0.85%       0.99%       
Return on                                                                   
 average                                                                    
 equity             9.41%      10.90%               9.69%      11.23%       
Net interest                                                                
 margin                                                                     
 (FTE)              3.84%       3.73%               3.78%       3.73%       
                                                                            
Loan Charge-                                                                
 Offs                                                                       
------------                                                                
Net loan                                                                    
 charge-offs $     1,484 $     1,167         $     4,556 $     3,196        
Net loan                                                                    
 charge-offs                                                                
 / average                                                                  
 loans              0.32%       0.30%               0.27%       0.22%       
                                                                            

The following is a non-GAAP disclosure of pre-tax net income excluding the effects of net realized gains on the sale of available for sale securities and one-time expenses including prepayment penalties on long-term borrowings, core processing conversion costs, and merger costs:

                                                                            
                              (unaudited)                                   
                          Three Months Ended         Twelve Months Ended    
                             December 31,               December 31,        
                       -------------------------  ------------------------- 
                                      (Dollars in thousands)                
                                           (unaudited)                      
                                                                            
                                            %                          %    
                         2016    2015    change    2016     2015    change  
                       -------- -------  -------  -------  -------  ------- 
                                                                            
Pre-tax net income,                                                         
 GAAP basis            $  7,067 $ 7,590     -6.9% $27,711  $30,489     -9.1%
Net realized (gains)                                                        
 losses on available-                                                       
 for-sale securities          -    (102)  -100.0%  (1,005)    (666)    51.2%
Prepayment penalties -                                                      
 long-term borrowings         -       -       NA    1,506        -       NA 
Core processing                                                             
 conversion costs            96     108    -11.1%   1,693      108   1467.6%
Merger costs                  5     308    -98.4%     486      308     57.8%
                       -------- -------           -------  -------          
Pre-tax net income,                                                         
 non-GAAP              $  7,168 $ 7,904     -9.3% $30,391  $30,239      0.5%
                       ======== =======           =======  =======          
                                                                            
                                                                            
                    (unaudited)  (unaudited)                                
                                  September     December                    
                    December 31       30          31,       % change versus 
                                                           ---------------- 
                                                                    12/31/1 
                        2016         2016         2015     9/30/16     5    
                    -----------  -----------  -----------  -------  ------- 
                     (Dollars in thousands, except share                    
                             and per share data)                            
Ending Balance                                                              
 Sheet                                                                      
Loans, net of                                                               
 unearned income    $ 1,870,870  $ 1,800,858  $ 1,577,798      3.9%    18.6%
Loans held for sale      10,194        2,814        1,381    262.3%   638.2%
Investment                                                                  
 securities             500,693      511,388      550,619     -2.1%    -9.1%
FHLB and other                                                              
 equity interests        19,186       18,334       15,921      4.6%    20.5%
Other earning                                                               
 assets                   2,246        2,117        3,959      6.1%   -43.3%
                    -----------  -----------  -----------                   
  Total earning                                                             
   assets             2,403,189    2,335,511    2,149,678      2.9%    11.8%
                                                                            
Allowance for loan                                                          
 losses                 (16,330)     (15,703)     (16,737)     4.0%    -2.4%
Goodwill                 38,730       38,967       27,194     -0.6%    42.4%
Core deposit                                                                
 intangible               2,854        3,200        2,395    -10.8%    19.2%
Other assets            145,378      177,969      122,606    -18.3%    18.6%
                    -----------  -----------  -----------                   
  Total assets      $ 2,573,821  $ 2,539,944  $ 2,285,136      1.3%    12.6%
                    ===========  ===========  ===========                   
                                                                            
Non interest-                                                               
 bearing deposits   $   289,922  $   293,049  $   263,639     -1.1%    10.0%
Interest-bearing                                                            
 deposits             1,727,600    1,730,732    1,551,414     -0.2%    11.4%
                    -----------  -----------  -----------                   
  Total deposits      2,017,522    2,023,781    1,815,053     -0.3%    11.2%
                                                                            
Borrowings              237,004      205,202      220,515     15.5%     7.5%
Subordinated debt        70,620       70,620       20,620      0.0%   242.5%
Deposits held for                                                           
 sale                     6,456            -            -       NA       NA 
Other liabilities        30,435       24,852       27,035     22.5%    12.6%
                                                                            
Common stock                  -            -            -       NA       NA 
Additional paid in                                                          
 capital                 77,737       77,543       77,827      0.3%    -0.1%
Retained earnings       134,295      131,643      123,301      2.0%     8.9%
Treasury stock             (127)        (163)      (1,114)   -22.1%   -88.6%
Accumulated other                                                           
 comprehensive                                                              
 income (loss)             (121)       6,466        1,899   -101.9%      NA 
                    -----------  -----------  -----------                   
  Total                                                                     
   shareholders'                                                            
   equity               211,784      215,489      201,913     -1.7%     4.9%
                    -----------  -----------  -----------                   
                                                                            
  Total liabilities                                                         
   and                                                                      
   shareholders'                                                            
   equity           $ 2,573,821  $ 2,539,944  $ 2,285,136      1.3%    12.6%
                    ===========  ===========  ===========                   
                                                                            
Ending shares                                                               
 outstanding         14,467,815   14,465,210   14,408,430                   
                                                                            
Book value per                                                              
 share              $     14.64  $     14.90  $     14.01                   
Tangible book value                                                         
 per share (*)      $     11.76  $     11.98  $     11.96                   
                                                                            
Capital Ratios                                                              
Tangible common                                                             
 equity / tangible                                                          
 assets (*)                6.72%        6.94%        7.64%                  
Tier 1 leverage                                                             
 ratio                     7.87%        7.71%        8.73%                  
Common equity tier                                                          
 1 ratio                   9.28%        9.43%       10.90%                  
Tier 1 risk based                                                           
 ratio                    10.33%       10.52%       12.14%                  
Total risk based                                                            
 ratio                    13.83%       14.11%       13.18%                  
                                                                            
Asset Quality                                                               
Non-accrual loans   $    15,329  $    15,325  $    12,159                   
Loans 90+ days past                                                         
 due and accruing            10           70          105                   
                    -----------  -----------  -----------                   
  Total non-                                                                
   performing loans      15,339       15,395       12,264                   
Other real estate                                                           
 owned                    1,057        1,147          925                   
                    -----------  -----------  -----------                   
  Total non-                                                                
   performing                                                               
   assets           $    16,396  $    16,542  $    13,189                   
                    ===========  ===========  ===========                   
                                                                            
Loans modified in a                                                         
 troubled debt                                                              
 restructuring                                                              
 (TDR):                                                                     
  Performing TDR                                                            
   loans            $     8,710  $     8,870  $     9,304                   
  Non-performing                                                            
   TDR loans (**)         3,120        3,202        5,637                   
                    -----------  -----------  -----------                   
    Total TDR loans $    11,830  $    12,072  $    14,941                   
                    ===========  ===========  ===========                   
                                                                            
Non-performing                                                              
 assets / Loans +                                                           
 OREO                      0.88%        0.92%        0.84%                  
Non-performing                                                              
 assets / Total                                                             
 assets                    0.64%        0.65%        0.58%                  
Allowance for loan                                                          
 losses / Loans            0.87%        0.87%        1.06%                  
                                                                            
                                                                            
* - Tangible common equity, tangible assets and tangible book value per     
share are non-GAAP financial measures calculated using GAAP amounts.        
Tangible common equity is calculated by excluding the balance of goodwill   
and other intangible assets from the calculation of stockholders' equity.   
Tangible assets is calculated by excluding the balance of goodwill and other
intangible assets from the calculation of total assets. Tangible book value 
per share is calculated by dividing tangible common equity by the number of 
shares outstanding. CNB believes that these non-GAAP financial measures     
provide information to investors that is useful in understanding its        
financial condition. Because not all companies use the same calculation of  
tangible common equity and tangible assets, this presentation may not be    
comparable to other similarly titled measures calculated by other companies.
A reconciliation of these non-GAAP financial measures is provided below     
(dollars in thousands, except per share data).                              
** - Nonperforming TDR loans are also included in the balance of non-accrual
loans in the previous table.                                                
                                                                            
                                                                            
                                (Dollars in thousands, except share and per 
                                                share data)                 
                                 (unaudited)    (unaudited)                 
                                 December 31    September 30   December 31, 
                                     2016           2016           2015     
                                -------------  -------------  ------------- 
                                                                            
Shareholders' equity            $     211,784  $     215,489  $     201,913 
  Less goodwill                        38,730         38,967         27,194 
  Less core deposit intangible          2,854          3,200          2,395 
                                -------------  -------------  ------------- 
Tangible common equity          $     170,200  $     173,322  $     172,324 
                                =============  =============  ============= 
                                                                            
Total assets                    $   2,573,821  $   2,539,944  $   2,285,136 
  Less goodwill                        38,730         38,967         27,194 
  Less core deposit intangible          2,854          3,200          2,395 
                                -------------  -------------  ------------- 
Tangible assets                 $   2,532,237  $   2,497,777  $   2,255,547 
                                =============  =============  ============= 
                                                                            
Ending shares outstanding          14,467,815     14,465,210     14,408,430 
                                                                            
Tangible book value per share   $       11.76  $       11.98  $       11.96 
Tangible common equity/Tangible                                             
 assets                                  6.72%          6.94%          7.64%
                                                                            

Celgene recebe parecer positivo da CHMP para expandir a indicação de REVLIMID® (lenalidomida) como monoterapia para o tratamento de manutenção em pacientes com Mieloma Múltiplo (MM) recém-diagnosticados após transplante autólogo de células estaminais

Submit the press release

BOUDRY, Suíça–(BUSINESS WIRE)–Celgene International Sàrl, uma subsidiária integral da Celgene Corporation (NASDAQ:CELG), anunciou hoje que o Comitê de Medicamentos para Uso Humano (CHMP) da Agência Europeia de Medicamentos (EMA) emitiu um parecer positivo para o uso de REVLIMID® como monoterapia para o tratamento de manutenção de pacientes adultos com mieloma múltiplo (MM) recém-diagnosticados que foram submetidos a transplante autólogo de células estaminais (TACE). Uma vez aprovado pela Comissão Europeia, o REVLIMID® será o primeiro e único tratamento de manutenção licenciado disponível para esses pacientes.

O mieloma múltiplo é um câncer de sangue incurável e com risco de vida que se caracteriza pela proliferação tumoral e supressão do sistema imunológico.1 É uma doença rara e potencialmente mortal – cerca de 39.000 pessoas são diagnosticadas com MM na Europa e cerca de 24.000 pessoas morrem da doença a cada ano.2 A idade média no diagnóstico na Europa é entre 65 e 70 anos.3 Na Europa, os pacientes com menos de 65 anos, em bom estado de saúde e em boas condições físicas são normalmente considerados elegíveis para TACE.4

Para os pacientes recém-diagnosticados com MM e elegíveis para transplante, os principais objetivos do tratamento são obter e manter uma resposta profunda ao tratamento, com o objetivo final de retardar a progressão da doença.5,6 Estes pacientes geralmente recebem terapia de indução e altas doses de quimioterapia com melfalano seguido por TACE. Esta estratégia de tratamento tem sido o padrão estabelecido de cuidados vigente por mais de 20 anos.7 Considerando que mais de metade dos pacientes apresentam recidiva no prazo de 2 a 3 anos após TACE,8,9 foram realizados estudos para avaliar se o tratamento de manutenção após TACE poderia possibilitar remissões mais duradouras.

“Estudos mostram que o tratamento de manutenção com REVLIMID®após TACE pode ajudar a controlar células malignas residuais e retardar o crescimento tumoral através do reforço da função imunológica”, disse Professor Michel Attal, diretor executivo do Instituto Universitário de Câncer Toulouse Oncopole e Instituto Claudius Regaud da França. “Nosso principal objetivo é retardar a progressão da doença o máximo de tempo possível, e vimos em vários estudos independentes que a manutenção de REVLIMID®após o TACE pode reduzir para metade o risco de progressão da doença, mantendo a resposta.”

A recomendação do CHMP baseou-se nos resultados de dois estudos conduzidos por grupos de cooperação, CALGB 10010410 e IFM 2005-0211:

  • • O CALGB 100104 é estudo multicêntrico de fase 3, duplo-cego, controlado de 460 pacientes com MM recém-diagnosticados submetidos a TACE que receberam tratamento diário contínuo com REVLIMID® ou placebo até a reincidência.
  • O IFM 2005-02 é um estudo internacional, de fase 3, controlado, duplo-cego e multicêntrico de 614 pacientes com MM recém-diagnosticados que foram randomizados para receber um esquema de consolidação de 2 meses pós-TACE de monoterapia de REVLIMID®, seguido de tratamento diário contínuo com REVLIMID® ou placebo até a reincidência.

Nos dois estudos de fase III, a monoterapia de REVLIMID® como tratamento de manutenção pós-TACE reduziu significativamente o risco de progressão da doença ou morte em pacientes com MM, permitindo a quebra da ocultação dos estudos baseados na passagem de seus limites pré-especificados para superioridade na análise intermediária.

Nestes estudos, o perfil de segurança estava em consonância com outros dados clínicos em um novo diagnóstico de transplante de células não-estaminais (NSTC) e estudo de segurança posterior à aprovação em MM recidiva/refratária (MMrr). Em ambos os estudos clínicos de fase III, os eventos adversos (EA) hematológicos mais frequentes relatados foram neutropenia e trombocitopenia. Os EA não hematológicos mais frequentemente notificados foram infecções. Em ambos os estudos foi observada uma taxa de incidência aumentada do segundo tumor primário (STP) hematológico no grupo REVLIMID® em comparação com o grupo placebo. No entanto, o parecer positivo do CHMP confirma que a relação benefício-risco para REVLIMID® é positiva nesta indicação ampliada.

Tuomo Pätsi, presidente da Celgene na Europa, Oriente Médio e África (EMEA), disse: “Apesar dos progressos substanciais realizados até agora no tratamento do mieloma múltiplo, continuamos a enfrentar uma doença incurável. Agradecemos este parecer do CHMP, uma vez que confirma o importante papel que o REVLIMID®desempenha no tratamento do mieloma múltiplo, estendendo o uso de REVLIMID®durante as diferentes fases da doença. Na Celgene, aspiramos transformar algumas das doenças mais desafiadoras, como o mieloma múltiplo, em condições controláveis. Desta forma, continuaremos a investir mais de um terço de nossas receitas em pesquisa e desenvolvimento.”

O CHMP analisa as inscrições de todos os 28 Estados-Membros da União Europeia (UE), bem como da Noruega, Liechtenstein e Islândia. A Comissão Europeia, que geralmente segue a recomendação do CHMP, deverá tomar sua decisão final em aproximadamente dois meses. Se a aprovação for concedida, as condições detalhadas para a utilização deste produto serão descritas no Resumo das Características do Medicamento (RCM), que será publicado no Relatório Público Europeu de Avaliação (EPAR).

Sobre o CALGB 100104

CALGB 100104 é um estudo de fase 3, multicêntrico, randomizado, duplo cego realizado em 47 centros nos Estados Unidos. 460 pacientes com mieloma múltiplo recém diagnosticados – com idade entre 18 e 70 anos – que alcançaram pelo menos doença estável (SD) ou melhor, 100 dias após serem submetidos a transplante autólogo de células estaminais (TACE), foram randomizados para receber manutenção de REVLIMID® (dose de 10 mg/dia por três meses, e posteriormente 15 mg/dia) ou placebo até progressão da doença, efeitos colaterais intoleráveis ou morte.

Sobre o IFM 2005-02

IFM 2005-02 é um estudo de fase 3,controlado, multicêntrico, duplo-cego, realizado em 77 centros em 3 países na Europa. 614 pacientes recentemente diagnosticados com mieloma múltiplo com menos de 65 anos sem sinais de progressão da doença nos seis meses após terem sido submetidos a TACE foram randomizados para receber um regime de consolidação de dois meses de monoterapia de REVLIMID® com dose de 25 mg por dia em 21/28 dias, seguidos de manutenção de REVLIMID® (dose de 10 mg/dia durante três meses, e posteriormente, 15 mg/dia) ou placebo até a progressão da doença, efeitos colaterais intoleráveis ou morte.

Sobre o REVLIMID®

REVLIMID® em combinação com dexametasona é aprovado na Europa, nos Estados Unidos, no Japão e em cerca de 30 outros países para o tratamento de pacientes adultos com mieloma múltiplo (MM) previamente não tratado que não são elegíveis para transplante. REVLIMID® é aprovado também em combinação com dexametasona para o tratamento de pacientes com MM que receberam pelo menos um tratamento prévio em quase 70 países, englobando a Europa, Américas, Oriente Médio e Ásia, e em combinação com dexametasona para o tratamento dos pacientes cuja doença progrediu após um tratamento na Austrália e na Nova Zelândia.

REVLIMID® também é aprovado nos Estados Unidos, Canadá, Suíça, Austrália, Nova Zelândia e vários países da América Latina, bem como na Malásia e Israel, para anemia dependente de transfusão devida a síndromes mielodisplásicas (SMD) de risco baixo ou intermediário associada a uma anormalidade citogenética deleção 5q com ou sem anomalias citogenéticas adicionais e na Europa para o tratamento de pacientes com anemia dependente de transfusão devida a SMD de risco baixo ou intermediário associada a uma isolada anormalidade citogenética deleção 5q, quando outras opções terapêuticas são insuficientes ou inadequadas.

Além disso, REVLIMID® é aprovado na Europa e nos Estados Unidos para o tratamento de pacientes com linfoma de células do manto (LCM) cuja doença teve recidiva ou progrediu após dois tratamentos anteriores, um dos quais incluiu bortezomibe. Na Suíça, o REVLIMID está indicado no tratamento de pacientes com MCL recidivante ou refratário após tratamento prévio que incluiu bortezomibe e quimioterapia/rituximabe.

INFORMAÇÕES DE SEGURANÇA IMPORTANTES ADICIONAIS baseadas no RCM da UE

Contraindicações

O REVLIMID® (lenalidomida) é contraindicado para pacientes com hipersensibilidade conhecida à substância ativa ou a qualquer dos excipientes na formulação.

REVLIMID® (lenalidomida) é contraindicado durante a gravidez, e também em mulheres em idade fértil, a menos que todas as condições do Programa de Prevenção da Gravidez sejam atendidas.

Avisos e Precauções

Gravidez: as condições do Programa de Prevenção da Gravidez devem ser cumpridas para todos os pacientes, a menos que haja evidência confiável de que o paciente não tem potencial para engravidar.

Doenças cardiovasculares: os pacientes com fatores de risco conhecidos para infarto do miocárdio ou tromboembolismo devem ser cuidadosamente monitorizados.

Neutropenia e trombocitopenia: o hemograma completo deve ser realizado semanalmente durante as primeiras oito semanas de tratamento e mensalmente para monitorizar as citopenias. Pode ser necessária uma redução da dose.

Infecção com ou sem neutropenia: todos os pacientes devem ser orientados a procurar atendimento médico imediatamente após o primeiro sinal de infecção.

Insuficiência renal: a monitorização da função renal é aconselhada em pacientes com insuficiência renal.

Transtornos da tiroide: recomenda-se o controle ótimo das condições co-mórbidas que influenciam a função da tireoide antes do início do tratamento. Recomenda-se a monitorização da avaliação inicial e contínua da função da tiroide.

Síndrome de lise tumoral: os pacientes com elevada carga tumoral antes do tratamento devem ser cuidadosamente monitorizados e devem ser tomadas precauções adequadas.

Reações alérgicas: pacientes que tiveram reações alérgicas anteriores durante o tratamento com talidomida devem ser cuidadosamente monitorizados.

Reações cutâneas graves: REVLIMID® (lenalidomida) deve ser descontinuado para irritações esfoliativas ou com bolhas, ou se suspeita de SJS ou TEN e não deve ser retomada após a interrupção devido a estas reações. A interrupção ou descontinuação da lenalidomida deve ser considerada em caso de irritações na pele dependendo da gravidade. Os pacientes com histórico de erupção cutânea grave associada ao tratamento com talidomida não devem receber lenalidomida.

Intolerância à lactose: pacientes com problemas hereditários raros de intolerância à galactose, deficiência de lactase Lapp ou má absorção de glucose-galactose não devem tomar este medicamento.

Segundo tumor primário (STP): o risco de ocorrência de STP hematológico deve ser levado em consideração antes de iniciar o tratamento com REVLIMID® (lenalidomida), seja em combinação com melfalano, seja imediatamente após uma dose elevada de melfalano e transplante autólogo de células estaminais (TACE). Os médicos devem avaliar cuidadosamente os pacientes antes e durante o tratamento utilizando a triagem padrão de câncer para a ocorrência de STP e iniciar o tratamento como indicado.

Doenças hepáticas: devem ser efetuados ajustamentos de dose em pacientes com insuficiência renal. Recomenda-se a monitorização da função hepática, especialmente quando existe um histórico de infecção hepática viral concomitante ou quando o REVLIMID® (lenalidomida) é combinado com medicamentos conhecidos por estarem associados com disfunção hepática.

Pacientes recém-diagnosticados com mieloma múltiplo: os pacientes devem ser cuidadosamente avaliados quanto à sua capacidade para tolerar REVLIMID® (lenalidomida) em combinação, considerando a idade, estágio ISS III, ECOG PS≤2 ou CLcr <60 ml/min.

Catarata: recomenda-se a monitorização regular da capacidade visual.

Resumo do perfil de segurança em mieloma múltiplo

Mieloma múltiplo recentemente diagnosticado em pacientes tratados com REVLIMID® (lenalidomida) em combinação com baixa dose de dexametasona:

  • As reações adversas graves observadas com mais frequência (≥ 5%) com REVLIMID® (lenalidomida) em combinação com baixas doses de dexametasona (Rd e Rd18) do que com melfalano, prednisona e talidomida (MPT) foram pneumonia (9,8%) e insuficiência renal (inclusive aguda) (6,3%).
  • As reações adversas observadas mais frequentemente com Rd ou Rd18 do que com MPT foram: diarreia (45,5%), fadiga (32,8%), dor nas costas (32,0%), astenia (28,2%), insônia (27,6%) e erupção cutânea , diminuição do apetite (23,1%), tosse (22,7%), pirexia (21,4%) e espasmos musculares (20,5%).

Pacientes com mieloma múltiplo recém diagnosticados tratados com REVLIMID® (lenalidomida) em combinação com melfalano e prednisona:

  • As reações adversas graves observadas com mais frequência (≥ 5%) com melfalano, prednisona e REVLIMID® seguidas de manutenção de REVLIMID® (lenalidomida) (MPR + R) ou melfalano, prednisona e REVLIMID® (lenalidomida) seguida por placebo (MPR + p) do que melfalano, prednisona e placebo seguido de placebo (MPp + p) foram neutropenia febril (6,0%) e anemia (5,3%).
  • As reações adversas observadas mais frequentemente com MPR + R ou MPR + p que MPp + p foram: neutropenia (83,3%), anemia (70,7%), trombocitopenia (70,0%), leucopenia (38,8%), constipação (34,0% diarreia (33,3%), erupção cutânea (28,9%), pirexia (27,0%), edema periférico (25,0%), tosse (24,0%), diminuição do apetite (23,7%) e astenia (22,0%).

Pacientes com mieloma múltiplo que tenham recebido pelo menos um tratamento anterior:

  • As reações adversas mais graves observadas mais frequentemente com REVLIMID® (lenalidomida) e dexametasona em comparação com placebo e dexametasona em combinação foram tromboembolismo venoso (trombose venosa profunda, embolia pulmonar) e neutropenia de grau 4.
  • As reações adversas observadas mais frequentemente com REVLIMID® e dexametasona em comparação a placebo e dexametasona em estudos clínicos combinados de mieloma múltiplo (MM-009 e MM-010) foram fadiga (43,9%), neutropenia (42,2%), constipação 40,5%), diarreia (38,5%), cãibras musculares (33,4%), anemia (31,4%), trombocitopenia (21,5%) e erupção cutânea (21,2%).

Populações especiais

População pediátrica: REVLIMID® (lenalidomida) não deve ser utilizado em crianças e adolescentes desde o nascimento até os 18 anos.

Idosos com mieloma múltiplo recentemente diagnosticado: para pacientes com idade superior a 75 anos tratados com REVLIMID® (lenalidomida) em combinação com dexametasona, a dose inicial de dexametasona é de 20 mg/dia nos dias 1, 8, 15 e 22 de cada ciclo de tratamento de 28 dias. Nenhum ajuste de dose é proposto para pacientes com mais de 75 anos tratados com REVLIMID® (lenalidomida) em combinação com melfalano e prednisona.

Idosos com mieloma múltiplo que tenham recebido pelo menos um tratamento anterior: deve ser tomado cuidado na seleção da dose e pode ser prudente monitorar a função renal.

Pacientes com insuficiência renal: deve ser tomado cuidado na seleção da dose e é aconselhável monitorização da função renal. Não são necessários ajustes de dose em pacientes com insuficiência renal leve e mieloma múltiplo. Recomendamos o ajuste da dose no início da terapia e durante todo o tratamento para pacientes com insuficiência renal moderada ou grave ou doença renal em fase terminal.

Pacientes com insuficiência hepática: REVLIMID® (lenalidomida) não foi estudado formalmente em pacientes com comprometimento da função hepática e não existem recomendações de dose específica.

Consulte o Resumo das Características do Produto para obter informações europeias de prescrição completas.

SOBRE A CELGENE

A Celgene International Sàrl, localizada em Boudry, Suíça, é uma subsidiária integral e sede internacional da Celgene Corporation. A Celgene Corporation, sediada em Summit, Nova Jersey, é uma empresa biofarmacêutica global integrada envolvida principalmente na descoberta, desenvolvimento e comercialização de terapias inovadoras para o tratamento do câncer e doenças inflamatórias através de soluções de próxima geração em homeostase de proteínas, imuno-oncologia, epigenética, imunologia e neuro inflamação. Para mais informações, acesse www.celgene.com. Siga a Celgene na mídia social: @Celgene, Pinterest, LinkedIn, FaceBook e YouTube.

DECLARAÇÕES PROSPECTIVAS

Este comunicado de imprensa contém declarações prospectivas, que geralmente são declarações que não são fatos históricos. Declarações prospectivas podem ser identificadas pelos termos „esperam”, „antecipam”, „acreditam”, „intenciona”, „estima”, „planos”, „irá” e „perspectiva”, e expressões similares. Qualquer declaração de previsão futura contida neste documento se baseia nas convicções e expectativas atuais de nossa administração, estimativas, suposições e projeções, e se refere somente à data na qual foram feitas. A Celgene não assume qualquer obrigação pela atualização estas declarações prospectivas, exceto conforme exigido por lei. As declarações de previsões futuras estão sujeitas a uma série de riscos e incertezas, das quais muitas são difíceis de prever e geralmente estão fora do nosso controle. Os resultados atuais e futuros podem ser materialmente diferentes dos resultados implicados nas declarações de previsões futuras como resultado de uma série de fatores, muitos dos quais estão descritos mais detalhadamente em nosso Relatório Anual no Formulário 10-K e em outros relatórios apresentados à Securities and Exchange Commission (Comissão de Valores Mobiliários dos EUA).

Todas as marcas registradas são de propriedade da Celgene Corporation.

________________________________

1 Palumbo A, et al. N Engl J Med. 2011;364:1046–1060.
2 Ferlay J, et al. Eur J Cancer. 2013;49:1374–1403
3 Moreau P, et al. Ann Oncol. 2013; 24 (Suppl 6): vi133-vi137
4 Moreau P, et al. Ann Oncol. 2013; 24 (Suppl 6): vi133-vi137
5 Stewart AK, et al. Blood. 2009;114:5436-5443.
6 Hoering A, et al. Blood. 2009;114:1299-1305
7 Bird JM, et al. Br J Haematol. 2011;154:32-75
8 Attal M, et al. Blood. 2006 Nov 15;108(10):3289-94
9 Child JA, et al. N Engl J Med. 2003; 348:1875-1883
10 McCarthy PL, et al. N Engl J Med. 2012;366(19):1770-1781. CALGB é o grupo cooperativo Câncer e Leucemia Grupo B (agora conhecido como Alliance).
11 Attal M, et al. N Engl J Med. 2012;366(19):1782-1791. IFM é o grupo cooperativo da Intergroupe Francophone du Myélome.

O texto no idioma original deste anúncio é a versão oficial autorizada. As traduções são fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que é a única versão do texto que tem efeito legal.

Les meilleures entreprises récompensées lors d’un événement exclusif à Stockholm

Submit the press release

STOCKHOLM, January 27, 2017 /PRNewswire/ —

Les meilleures entreprises de Suède, de Norvège, de Finlande et d’Islande ont été mises à l’honneur lors d’un événement exclusif hier soir à Stockholm, dans le cadre des European Business Awards sponsorisés par RSM.

     (Photo: http://mma.prnewswire.com/media/462118/Nordic_National_Champions.jpg )

Les 54 entreprises ont été choisies par un jury indépendant composé de chefs d’entreprise et d’universitaires de haut rang pour être les « champions nationaux » de la plus grande compétition d’entreprises d’Europe.

Au cours de cet événement, le septième d’une série d’événements organisés à travers l’Europe, les participants ont eu la possibilité de s’entretenir avec des entreprises renommées dans leur domaine d’activité et d’écouter les conférenciers invités s’exprimer, notamment Robert Hasslund, associé directeur de RSM Sweden.

Adrian Tripp, PDG des European Business Awards, a déclaré : « Ces événements célèbrent non seulement le succès de nos dynamiques champions nationaux dans le cadre de la compétition, mais également le rôle essentiel qu’ils jouent dans le puissant milieu d’affaires européen. Je félicite tous nos champions nationaux des pays nordiques pour leur réussite. »

RSM, principal sponsor de la compétition, est le sixième plus grand réseau d’entreprises indépendantes d’audit, de fiscalité et de conseil au monde, et apporte son soutien aux European Business Awards depuis leur création.

Robert Hasslund, partenaire de RSM Sweden, a déclaré : « C’est un immense plaisir de voir tant d’entreprises nordiques prospères développer leur réseau et établir de nouvelles relations. Chez RSM Sweden, nous sommes très satisfaits de cet événement et nous souhaitons à tous les champions nationaux un franc succès à l’avenir. »

Jean Stephens, PDG de RSM, a déclaré : « Les champions nationaux sont des leaders qui se démarquent, font preuve de ténacité dans les affaires et d’excellence commerciale. Ces entreprises ouvriront la voie et apporteront la croissance et la prospérité à travers le continent et au-delà. Je souhaite tous les féliciter et leur souhaiter bonne chance pour les prochains tours. »

Lors du prochain tour, les champions nationaux prendront part au vote du public, qui est ouvert depuis le 9 janvier à l’adresse http://www.businessawardseurope.com. Les vainqueurs de chaque catégorie et le grand gagnant du vote du public seront annoncés lors du gala final, en mai 2017.

Les European Business Awards ont été créés pour favoriser le développement d’un milieu d’affaires plus solide et plus prospère à travers l’Europe. Cette année, ils ont vu participer plus de 33 000 entreprises de 34 pays différents.

Pour de plus amples informations sur les champions nationaux et les European Business Awards, rendez-vous à l’adresse http://www.businessawardseurope.com ou http://www.rsm.global

À propos des European Business Awards :   

L’objectif premier des European Business Awards est de soutenir le développement d’un milieu d’affaires plus robuste et plus performant à travers l’Europe.

Pour tous les citoyens européens, la prospérité et les systèmes sociaux et de santé dépendent de la capacité des entreprises à créer un milieu d’affaires encore plus robuste, innovant, performant, international et éthique ; un milieu d’affaires qui soit le cœur même d’une économie de plus en plus mondialisée.

Le programme European Business Awards poursuit trois objectifs au profit du milieu d’affaires européen :

•    Célébrer et soutenir la réussite des individus et des entreprises

•    Offrir et promouvoir des exemples d’excellence à suivre par le milieu d’affaires

•    Stimuler le débat sur des sujets clés au sein du milieu d’affaires européen

Les European Business Awards en sont maintenant à leur 10e édition. Cette année, ils ont vu participer plus de 33 000 entreprises de 34 pays différents. La compétition de l’an passé a comptabilisé plus de 227 000 votes du public à travers l’Europe. Les sponsors et les partenaires de la compétition incluent RSM, ELITE et PR Newswire.

http://www.businessawardseurope.com.

À propos de RSM :   

RSM est le sixième plus grand réseau d’entreprises indépendantes d’audit, de fiscalité et de conseil, englobant plus de 120 pays, 760 bureaux et 38 000 personnes dans le monde. Au total, les honoraires du réseau se chiffrent à 4,64 milliards de dollars américains.

RSM est le principal sponsor et le défenseur des entreprises des European Business Awards, et sa mission consiste à promouvoir l’excellence commerciale et à récompenser le génie entrepreneurial.

RSM est membre du Forum of Firms, avec pour objectif partagé de promouvoir des normes de qualité élevées et uniformes en matière de pratiques financières et d’audit à travers le monde.

RSM est la marque utilisée par un réseau de sociétés de comptabilité et de conseil indépendantes qui exercent pour leur propre compte. RSM International Limited ne fournit pas directement des services de comptabilité et de conseil. Les entreprises membres partagent une vision des services professionnels de haute qualité, aussi bien sur leur marché national que pour répondre à la demande de services professionnels de leurs clients à l’international. http://www.rsm.global  

À propos dELITE :  

ELITE est un programme complet visant à partager les meilleures pratiques et à donner plus d’opportunités de croissance aux entreprises à forte croissance, en mettant l’accent sur la compréhension des marchés de capitaux. ELITE est un programme innovant basé sur une formation exclusive et un modèle de tutorat, bénéficiant d’un accès au milieu des affaires et à la communauté financière. Son objectif est de préparer les entreprises pour leur prochaine phase de croissance et d’investissement.

Pour de plus amples informations sur le programme, les entreprises et la liste complète des partenaires, rendez-vous sur le site :

http://www.elite-growth.com     

À propos de PR Newswire :  

PR Newswire est le premier fournisseur mondial de communiqués de presse et d’outils de communication d’entreprise permettant à ses clients de diffuser des informations et des contenus riches. Nous diffusons les contenus de nos clients à travers les canaux traditionnels, numériques et les réseaux sociaux en temps réel avec un suivi et des rapports entièrement exploitables.

Fort du plus grand réseau de distribution et d’optimisation de contenus multicanal et multiculturel au monde et d’une suite complète d’outils et de plateformes de workflow, PR Newswire permet aux entreprises du monde entier de saisir chaque occasion, où qu’elle se présente. PR Newswire est au service de dizaines de milliers de clients depuis ses bureaux situés en Europe, au Moyen-Orient, en Afrique, sur le continent américain et dans la région Asie-Pacifique.

Pour plus d’informations sur PR Newswire, rendez-vous à l’adresse http://www.prnewswire.co.uk

 

SOURCE European Business Awards and RSM

Les meilleures entreprises récompensées lors d’un événement exclusif à Stockholm

Submit the press release

STOCKHOLM, January 27, 2017 /PRNewswire/ —

Les meilleures entreprises de Suède, de Norvège, de Finlande et d’Islande ont été mises à l’honneur lors d’un événement exclusif hier soir à Stockholm, dans le cadre des European Business Awards sponsorisés par RSM.

     (Photo: http://mma.prnewswire.com/media/462118/Nordic_National_Champions.jpg )

Les 54 entreprises ont été choisies par un jury indépendant composé de chefs d’entreprise et d’universitaires de haut rang pour être les « champions nationaux » de la plus grande compétition d’entreprises d’Europe.

Au cours de cet événement, le septième d’une série d’événements organisés à travers l’Europe, les participants ont eu la possibilité de s’entretenir avec des entreprises renommées dans leur domaine d’activité et d’écouter les conférenciers invités s’exprimer, notamment Robert Hasslund, associé directeur de RSM Sweden.

Adrian Tripp, PDG des European Business Awards, a déclaré : « Ces événements célèbrent non seulement le succès de nos dynamiques champions nationaux dans le cadre de la compétition, mais également le rôle essentiel qu’ils jouent dans le puissant milieu d’affaires européen. Je félicite tous nos champions nationaux des pays nordiques pour leur réussite. »

RSM, principal sponsor de la compétition, est le sixième plus grand réseau d’entreprises indépendantes d’audit, de fiscalité et de conseil au monde, et apporte son soutien aux European Business Awards depuis leur création.

Robert Hasslund, partenaire de RSM Sweden, a déclaré : « C’est un immense plaisir de voir tant d’entreprises nordiques prospères développer leur réseau et établir de nouvelles relations. Chez RSM Sweden, nous sommes très satisfaits de cet événement et nous souhaitons à tous les champions nationaux un franc succès à l’avenir. »

Jean Stephens, PDG de RSM, a déclaré : « Les champions nationaux sont des leaders qui se démarquent, font preuve de ténacité dans les affaires et d’excellence commerciale. Ces entreprises ouvriront la voie et apporteront la croissance et la prospérité à travers le continent et au-delà. Je souhaite tous les féliciter et leur souhaiter bonne chance pour les prochains tours. »

Lors du prochain tour, les champions nationaux prendront part au vote du public, qui est ouvert depuis le 9 janvier à l’adresse http://www.businessawardseurope.com. Les vainqueurs de chaque catégorie et le grand gagnant du vote du public seront annoncés lors du gala final, en mai 2017.

Les European Business Awards ont été créés pour favoriser le développement d’un milieu d’affaires plus solide et plus prospère à travers l’Europe. Cette année, ils ont vu participer plus de 33 000 entreprises de 34 pays différents.

Pour de plus amples informations sur les champions nationaux et les European Business Awards, rendez-vous à l’adresse http://www.businessawardseurope.com ou http://www.rsm.global

À propos des European Business Awards :   

L’objectif premier des European Business Awards est de soutenir le développement d’un milieu d’affaires plus robuste et plus performant à travers l’Europe.

Pour tous les citoyens européens, la prospérité et les systèmes sociaux et de santé dépendent de la capacité des entreprises à créer un milieu d’affaires encore plus robuste, innovant, performant, international et éthique ; un milieu d’affaires qui soit le cœur même d’une économie de plus en plus mondialisée.

Le programme European Business Awards poursuit trois objectifs au profit du milieu d’affaires européen :

•    Célébrer et soutenir la réussite des individus et des entreprises

•    Offrir et promouvoir des exemples d’excellence à suivre par le milieu d’affaires

•    Stimuler le débat sur des sujets clés au sein du milieu d’affaires européen

Les European Business Awards en sont maintenant à leur 10e édition. Cette année, ils ont vu participer plus de 33 000 entreprises de 34 pays différents. La compétition de l’an passé a comptabilisé plus de 227 000 votes du public à travers l’Europe. Les sponsors et les partenaires de la compétition incluent RSM, ELITE et PR Newswire.

http://www.businessawardseurope.com.

À propos de RSM :   

RSM est le sixième plus grand réseau d’entreprises indépendantes d’audit, de fiscalité et de conseil, englobant plus de 120 pays, 760 bureaux et 38 000 personnes dans le monde. Au total, les honoraires du réseau se chiffrent à 4,64 milliards de dollars américains.

RSM est le principal sponsor et le défenseur des entreprises des European Business Awards, et sa mission consiste à promouvoir l’excellence commerciale et à récompenser le génie entrepreneurial.

RSM est membre du Forum of Firms, avec pour objectif partagé de promouvoir des normes de qualité élevées et uniformes en matière de pratiques financières et d’audit à travers le monde.

RSM est la marque utilisée par un réseau de sociétés de comptabilité et de conseil indépendantes qui exercent pour leur propre compte. RSM International Limited ne fournit pas directement des services de comptabilité et de conseil. Les entreprises membres partagent une vision des services professionnels de haute qualité, aussi bien sur leur marché national que pour répondre à la demande de services professionnels de leurs clients à l’international. http://www.rsm.global  

À propos dELITE :  

ELITE est un programme complet visant à partager les meilleures pratiques et à donner plus d’opportunités de croissance aux entreprises à forte croissance, en mettant l’accent sur la compréhension des marchés de capitaux. ELITE est un programme innovant basé sur une formation exclusive et un modèle de tutorat, bénéficiant d’un accès au milieu des affaires et à la communauté financière. Son objectif est de préparer les entreprises pour leur prochaine phase de croissance et d’investissement.

Pour de plus amples informations sur le programme, les entreprises et la liste complète des partenaires, rendez-vous sur le site :

http://www.elite-growth.com     

À propos de PR Newswire :  

PR Newswire est le premier fournisseur mondial de communiqués de presse et d’outils de communication d’entreprise permettant à ses clients de diffuser des informations et des contenus riches. Nous diffusons les contenus de nos clients à travers les canaux traditionnels, numériques et les réseaux sociaux en temps réel avec un suivi et des rapports entièrement exploitables.

Fort du plus grand réseau de distribution et d’optimisation de contenus multicanal et multiculturel au monde et d’une suite complète d’outils et de plateformes de workflow, PR Newswire permet aux entreprises du monde entier de saisir chaque occasion, où qu’elle se présente. PR Newswire est au service de dizaines de milliers de clients depuis ses bureaux situés en Europe, au Moyen-Orient, en Afrique, sur le continent américain et dans la région Asie-Pacifique.

Pour plus d’informations sur PR Newswire, rendez-vous à l’adresse http://www.prnewswire.co.uk

SOURCE European Business Awards and RSM